Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients
Clinical trial NCT02164006 · COMPLETED
Trial details
- NCT number
- NCT02164006
- Sponsor
- TG Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-06-11
- Primary completion
- 2016-05-01
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.